TNSN07319A1 - Derives d'oxindole servant d'agonistes du recepteur 5ht4 - Google Patents
Derives d'oxindole servant d'agonistes du recepteur 5ht4Info
- Publication number
- TNSN07319A1 TNSN07319A1 TNP2007000319A TNSN07319A TNSN07319A1 TN SN07319 A1 TNSN07319 A1 TN SN07319A1 TN P2007000319 A TNP2007000319 A TN P2007000319A TN SN07319 A TNSN07319 A TN SN07319A TN SN07319 A1 TNSN07319 A1 TN SN07319A1
- Authority
- TN
- Tunisia
- Prior art keywords
- disease
- compounds
- dyspepsia
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (I) : Ou un de leurs sels pharmaceutiquement acceptables, formule dans laquelle : A, R1, R2, R3, R4 et R5 sont chacun tels que définis ici ou représentent un de leurs sels pharmaceutiquement acceptables, et des compositions contenant ces composés, ainsi que l'utilisation de ces composés dans le traitement d'une affection à médiation par une activité agoniste de 5-HT4, telle que mais à titre non limitatif, la maladie de reflux gastro-aesophagien, une maladie gastro-intestinale, un trouble de la motilité gastrique, la dyspepsie non ulcéreuse, la dyspepsie fonctionnelle, le syndrome du colon irritable (IBS), la constipation, la dyspépsie, l'aesophagite, une maladie gastro-aesophagienne, les nausées, une maladie du système nerveux central, la maladie d'Alzheimer, un trouble cognitif, des états émétiques, la migraine, une maladie neurologique, la douleur, des troubles cardiovasculaires, l'insuffisance cardiaque, l'arythmie cardiaque, le diabète ou le syndrome d'apnée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65527605P | 2005-02-22 | 2005-02-22 | |
| PCT/IB2006/000519 WO2006090279A1 (fr) | 2005-02-22 | 2006-02-10 | Derives d'oxyindole utilises comme agonistes du recepteur 5ht4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN07319A1 true TNSN07319A1 (fr) | 2008-12-31 |
Family
ID=36579484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2007000319A TNSN07319A1 (fr) | 2005-02-22 | 2007-08-21 | Derives d'oxindole servant d'agonistes du recepteur 5ht4 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7589109B2 (fr) |
| EP (1) | EP1856110B1 (fr) |
| JP (1) | JP4130220B1 (fr) |
| KR (1) | KR100908547B1 (fr) |
| CN (1) | CN101522668B (fr) |
| AP (1) | AP2007004067A0 (fr) |
| AR (1) | AR053548A1 (fr) |
| AT (1) | ATE513827T1 (fr) |
| AU (1) | AU2006217534B8 (fr) |
| BR (1) | BRPI0607456A2 (fr) |
| CA (1) | CA2598536C (fr) |
| DK (1) | DK1856110T3 (fr) |
| DO (1) | DOP2006000046A (fr) |
| EA (1) | EA012615B1 (fr) |
| ES (1) | ES2366375T3 (fr) |
| GE (1) | GEP20094727B (fr) |
| GT (1) | GT200600083A (fr) |
| HN (1) | HN2006007884A (fr) |
| IL (1) | IL184505A0 (fr) |
| MA (1) | MA29260B1 (fr) |
| MX (1) | MX2007010139A (fr) |
| NL (1) | NL1031218C2 (fr) |
| NO (1) | NO20073566L (fr) |
| NZ (1) | NZ556627A (fr) |
| PE (1) | PE20061096A1 (fr) |
| TN (1) | TNSN07319A1 (fr) |
| TW (1) | TW200640915A (fr) |
| UA (1) | UA86301C2 (fr) |
| UY (1) | UY29389A1 (fr) |
| WO (1) | WO2006090279A1 (fr) |
| ZA (1) | ZA200706420B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU714980B2 (en) | 1996-07-24 | 2000-01-13 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
| AP2007004067A0 (en) * | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| CA2611639A1 (fr) * | 2005-06-29 | 2007-01-04 | Merck & Co., Inc. | 4-fluoro-piperidines antagonistes du canal calcium de type t |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2007086559A1 (fr) * | 2006-01-27 | 2007-08-02 | Ube Industries, Ltd. | Procede de fabrication d'un compose tetrahydropyrane |
| US20080051585A1 (en) * | 2006-08-17 | 2008-02-28 | Wyeth | Process for the preparation of indolin-2-one derivatives useful as PR modulators |
| MX2008010233A (es) * | 2008-03-10 | 2009-11-10 | Eurodrug Lab B V | Composicion de liberacion modificada, que comprende doxofilina. |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| ES2547415T3 (es) * | 2009-02-27 | 2015-10-06 | Raqualia Pharma Inc | Derivados de oxiindol con actividad agonista del receptor de motilina |
| KR101544246B1 (ko) * | 2009-05-07 | 2015-08-12 | 유나이티드 세러퓨틱스 코오포레이션 | 프로스타시클린 유사체의 고체 제제 |
| CA2771885C (fr) | 2009-09-14 | 2014-04-08 | Suven Life Sciences Limited | Composes de 1,2-dihydro-2-oxoquinoleine comme ligands des recepteurs 5-ht4 |
| WO2011099305A1 (fr) * | 2010-02-12 | 2011-08-18 | Raqualia Pharma Inc. | Agonistes du récepteur 5-ht4 pour le traitement de la démence |
| MX337721B (es) * | 2011-09-19 | 2016-03-16 | Suven Life Sciences Ltd | Compuestos de heteroarilo como ligandos del receptor 5-ht4. |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| EP3105219B9 (fr) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| DK3105226T3 (da) | 2014-02-13 | 2019-10-14 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
| EP3626720A1 (fr) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| WO2017141106A1 (fr) * | 2016-02-16 | 2017-08-24 | Strongbridge Biopharma plc | Veldoréotide de faible solubilité dans des conditions physiologiques destiné à être utilisé dans le traitement d'une acromégalie, d'un cancer associé à une acromégalie, de tumeurs exprimant le sst-r5, du diabète de type 2, d'une hyperglycémie, et de tumeurs associées aux hormones |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN114105863B (zh) * | 2021-12-07 | 2023-11-28 | 江苏汉拓光学材料有限公司 | 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552408A (en) * | 1987-09-23 | 1996-09-03 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists |
| US5223511A (en) * | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| WO1992012149A1 (fr) | 1991-01-09 | 1992-07-23 | Smithkline Beecham Plc | Derives azabicydiques et azatricydiques, leurs procedes et intermediaires de preparation et compositions pharmaceutiques les contenant |
| US5955470A (en) * | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9121170D0 (en) | 1991-10-05 | 1991-11-20 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5280028A (en) * | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
| US5300512A (en) * | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5521193A (en) * | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
| FR2694292B1 (fr) | 1992-07-29 | 1994-10-21 | Esteve Labor Dr | Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament. |
| US5705498A (en) * | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| TW251287B (fr) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9312348D0 (en) | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| US5534521A (en) * | 1993-06-23 | 1996-07-09 | G. D. Searle & Co. | Benzimidazole compounds |
| CA2134192A1 (fr) | 1993-11-12 | 1995-05-13 | Michael L. Denney | Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique |
| US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
| GB9414139D0 (en) * | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| DE4440675A1 (de) | 1994-11-14 | 1996-05-15 | Basf Ag | Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| DE69823843T2 (de) * | 1997-09-09 | 2005-05-12 | Bristol-Myers Squibb Pharma Co. | Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US6492375B2 (en) * | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| US6310059B1 (en) * | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
| WO2000026197A1 (fr) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Nouveaux inhibiteurs de l'enzyme impdh |
| WO2001046166A2 (fr) | 1999-12-20 | 2001-06-28 | Neuromed Technologies, Inc. | Inhibiteurs calciques partiellement satures |
| US20020128232A1 (en) | 2000-10-12 | 2002-09-12 | Henderson Scott A. | Heterocyclic angiogenesis inhibitors |
| AU3950802A (en) * | 2000-12-07 | 2002-06-18 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| DOP2003000703A (es) * | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| EP1637521B1 (fr) | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Nouveau compose heterocyclique tricyclique |
| OA13248A (en) * | 2003-09-03 | 2007-01-31 | Pfizer | Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity. |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AU2005254800B2 (en) * | 2004-06-15 | 2010-12-09 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AP2007004067A0 (en) * | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
-
2006
- 2006-02-10 AP AP2007004067A patent/AP2007004067A0/xx unknown
- 2006-02-10 MX MX2007010139A patent/MX2007010139A/es active IP Right Grant
- 2006-02-10 NZ NZ556627A patent/NZ556627A/en not_active IP Right Cessation
- 2006-02-10 GE GEAP200610234A patent/GEP20094727B/en unknown
- 2006-02-10 DK DK06710525.4T patent/DK1856110T3/da active
- 2006-02-10 JP JP2007556683A patent/JP4130220B1/ja not_active Expired - Fee Related
- 2006-02-10 AT AT06710525T patent/ATE513827T1/de not_active IP Right Cessation
- 2006-02-10 BR BRPI0607456-1A patent/BRPI0607456A2/pt not_active IP Right Cessation
- 2006-02-10 CN CN200680005786XA patent/CN101522668B/zh not_active Expired - Fee Related
- 2006-02-10 ES ES06710525T patent/ES2366375T3/es active Active
- 2006-02-10 WO PCT/IB2006/000519 patent/WO2006090279A1/fr not_active Ceased
- 2006-02-10 CA CA2598536A patent/CA2598536C/fr not_active Expired - Fee Related
- 2006-02-10 EA EA200701552A patent/EA012615B1/ru not_active IP Right Cessation
- 2006-02-10 AU AU2006217534A patent/AU2006217534B8/en not_active Ceased
- 2006-02-10 KR KR1020077019124A patent/KR100908547B1/ko not_active Expired - Fee Related
- 2006-02-10 EP EP06710525A patent/EP1856110B1/fr active Active
- 2006-02-20 PE PE2006000207A patent/PE20061096A1/es not_active Application Discontinuation
- 2006-02-20 DO DO2006000046A patent/DOP2006000046A/es unknown
- 2006-02-20 AR ARP060100601A patent/AR053548A1/es unknown
- 2006-02-21 TW TW095105776A patent/TW200640915A/zh unknown
- 2006-02-21 GT GT200600083A patent/GT200600083A/es unknown
- 2006-02-21 HN HN2006007884A patent/HN2006007884A/es unknown
- 2006-02-22 NL NL1031218A patent/NL1031218C2/nl not_active IP Right Cessation
- 2006-02-22 UY UY29389A patent/UY29389A1/es not_active Application Discontinuation
- 2006-02-22 US US11/360,095 patent/US7589109B2/en not_active Expired - Fee Related
- 2006-10-02 UA UAA200709522A patent/UA86301C2/uk unknown
-
2007
- 2007-07-09 IL IL184505A patent/IL184505A0/en unknown
- 2007-07-10 NO NO20073566A patent/NO20073566L/no not_active Application Discontinuation
- 2007-08-01 ZA ZA200706420A patent/ZA200706420B/xx unknown
- 2007-08-21 TN TNP2007000319A patent/TNSN07319A1/fr unknown
- 2007-08-22 MA MA30153A patent/MA29260B1/fr unknown
-
2009
- 2009-06-24 US US12/490,451 patent/US20100173925A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07319A1 (fr) | Derives d'oxindole servant d'agonistes du recepteur 5ht4 | |
| MA28667B1 (fr) | Derives d'acide benzimidazolonecarboxylique | |
| MA28021A1 (fr) | Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| HUT69704A (en) | Isatin derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same | |
| MA27775A1 (fr) | Composes organiques | |
| ZA200309004B (en) | Heterocyclylocy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands. | |
| MA29211B1 (fr) | Composes de thienopyridinone et methodes therapeutiques | |
| CA2048027C (fr) | Derives de 3-arylindole et de 3-arylindazole | |
| AU2004262484A1 (en) | Indol-6 sulfonamide derivatives, their preparation and their use 5-HT-6 as modulators | |
| TW200425894A (en) | Treatment of psychotic and depressive disorders | |
| PT1701940E (pt) | Derivados de 2-(1h-indolilsulfanil)-benzil-amina como ssri | |
| JPH01502757A (ja) | 向精神薬二環イミド類 | |
| ATE449092T1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| RU2163604C2 (ru) | Производные n-замещенных 3-азабицикло [3.2.0]гептанов и их соли с физиологически приемлемыми кислотами и фармацевтическая композиция с антипсихотической активностью | |
| CZ282054B6 (cs) | 1-/Pyrido/3,4-b/-1,4-oxazin-4-yl/-1H-indoly, meziprodukty a způsob jejich přípravy a jejich použití jako léčiv | |
| ES2202348T3 (es) | Derivados del azabicicloheptano n-substituidos, como por ejemplo neurolepticos. | |
| HUP0203839A2 (hu) | 4-Fenil-1-piperazinil-, -piperidinil- és tetrahidropiridil-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| BR112018000065B1 (pt) | Compostos de aril sulfonamida como inibidores de anidrase carbônica, composição farmacêutica compreendendo os ditos compostos e usos terapêuticos dos mesmos no tratamento de câncer | |
| EA011418B1 (ru) | Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи | |
| MA27852A1 (fr) | Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique | |
| JPS6257606B2 (fr) | ||
| TW460472B (en) | Process for preparing cyclic thioamides | |
| TH76314A (th) | สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด | |
| TH106943A (th) | สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์ |